New Analysis Suggests Treatment with Tracleer(R) (bosentan) is Associated with Improved Survival in Primary Pulmonary Hypertension
19 mai 2003 17h44 HE
|
Actelion Ltd.
ALLSCHWIL, BASEL, Switzerland, May 19, 2003 (PRIMEZONE) -- Actelion Ltd (Other OTC:ALIOF) (SWX:ATLN) today announced the analysis of long-term follow-up data of primary pulmonary hypertension...
Actelion Invitation to Investor Conference Call / Webcast
15 mai 2003 09h06 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, May 15, 2003 (PRIMEZONE) -- Actelion to host Conference Call/Webcast following ATS presentation by opinion leader Dr Vallerie McLaughlin on 19 May 2003 (Seattle)At the...
Actelion announces first quarter results 2003; sustainable profitability ahead of schedule
29 avr. 2003 02h07 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, April 29, 2003 (PRIMEZONE) -- Actelion Ltd (SWX: ATLN) today announced its financial results for the first quarter 2003.
- Q1 2003 with operating profit of CHF 3.7 million...
Actelion Shareholder Meeting in Basel, Switzerland
23 avr. 2003 10h27 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, April 23, 2003 (PRIMEZONE) -- At today's Annual General Meeting of Actelion Ltd. (SWX:ATLN) (Other OTC:ALIOF), shareholders approved the following measures:
- Increase in...
Actelion Ltd: American Thoracic Society Publishes Abstract on Positive Long-Term Survival Data with Tracleer (Bosentan) in Patients with Primary Pulmonary Hypertension
23 avr. 2003 01h48 HE
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland, April 23, 2003 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) (Other OTC:ALIOF):
At the upcoming American Thoracic Society (ATS) Scientific Sessions to be held in Seattle,...
Actelion files New Drug Application for Tracleer(R) in Japan; Actelion's Japanese Affiliate Prepared for Launch at the End of 2003
08 avr. 2003 01h52 HE
|
Actelion Ltd.
ALLSCHWIL, Switzerland, April 8, 2003 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) today announced that the company has submitted a new drug application (NDA) for Tracleer(R) for the...
Actelion Presents a Full and Promising Clinical Pipeline -- Strong R&D as Basis for Above-industry Growth
04 mars 2003 01h50 HE
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland, March 4, 2003 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) (Other OTC:ALIOF) today provided a complete overview of its clinical pipeline at its annual Analyst and Media Day....
Actelion Starts Launch of Zavesca in the European Union; Patients in U.K. First to Benefit from First Oral Treatment for Type-1 Gaucher's Disease -- Re-filing in the United States in Progress
03 mars 2003 01h58 HE
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland, March 3, 2003 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) (Other OTC:ALIOF) today announced that the company has started the introduction of Zavesca(R) in the European...
Actelion Announces Fourth Quarter and Full-year 2002 Financial Results Above Expectations
18 févr. 2003 01h54 HE
|
Actelion Ltd.
ALLSCHWIL and BASEL, Switzerland, Feb. 18, 2003 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) (Other OTC:ALIOF) today announced its financial results for the year 2002. With operating revenues more than...
Actelion 2002 Operating Revenues at CHF 140.3 Million
23 janv. 2003 02h29 HE
|
Actelion Ltd.
ALLSCHWIL and BASEL, Switzerland, Jan. 23, 2003 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) (Other OTC:ALIOF) today reported operating revenues for the year 2002 of CHF 140.3 million (2001: 64.1...